Company intelligence / Profile preview

Endotronix

Woodridge, Illinois, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Endotronix's Cordella Heart Failure System—including the FDA-approved implantable PA pressure sensor—enables daily remote physiologic monitoring of heart failure patients, reducing hospitalizations and improving patient outcomes. Clinical use has shown marked reductions in 6-month heart failure hospitalization/all-cause mortality (rate 0.159), and improved quality of life metrics (KCCQ scores, 6-minute walk test).

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health platform
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Endotronix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endotronix.

Explore the full profile